Providing the best research solutions to customers
ABOUT COMPANY

Providing the best research solutions to customers

We are a specialized Contract Research Organization (CRO) dedicated to advancing preclinical research in the field of obesity. Drawing on our deep expertise and innovative approaches, we strive to deliver high-quality data, actionable insights, and tailored solutions that drive breakthroughs in obesity therapeutics.

  • Comprehensive Obesity Model Evaluation
  • Cutting-Edge Analytical Capabilities
  • Multidisciplinary Research Expertise
  • Flexible and Scalable Service Offerings
  • Regulatory Compliance and Quality Assurance
Learn More +
DIVERSE PLATFORMS

We're providing variety therapy development services to you


ABOUT COMPANY

Offering comprehensive research solutions to global customers

Driven by a passion for scientific innovation and a commitment to client success, we have established a reputation for delivering high-quality data, actionable insights, and tailored solutions that drive breakthroughs in obesity therapeutics.

Learn More +
Comprehensive Research Solutions
  • Integrated Obesity Research Platform
    Our end-to-end platform seamlessly integrates expertise across diverse disciplines, including metabolism, inflammation, and cardiovascular biology, enabling a holistic approach to obesity research and therapy development.
  • Collaborative and Tailored Approach
    We work closely with our clients to understand their unique needs and tailor our services accordingly, fostering open communication and flexible project management to deliver personalized solutions that accelerate your drug development timelines.
  • Regulatory Compliance and Quality Assurance
    Adhering to the highest standards of GLP/GMP compliance and quality control, we ensure the integrity and regulatory acceptance of the data generated throughout our preclinical obesity research services.
BASIC RESEARCH

Comprehensive research services for understanding and addressing obesity

PRECLINICAL SERVICES

Advanced preclinical services for anti-obesity drug development

TARGETED RESEARCH

Targeted Research on Key Mechanisms in Obesity


Hormones and Peptides

We investigate the roles of hormones and peptides that regulate appetite, metabolism, and energy balance in obesity. By exploring their mechanisms of action, we aim to identify novel therapeutic targets for obesity management.

Receptors

Our research focuses on receptors involved in appetite regulation and energy homeostasis, examining their potential as targets for anti-obesity therapies. Understanding receptor activity can lead to new drug designs that effectively modulate weight and metabolic processes.

Enzymes and Proteins

We analyze key enzymes and proteins that play critical roles in metabolic pathways associated with obesity. This research helps to elucidate their functions and potential as therapeutic targets for developing effective obesity treatments.

Receptors and Pathways

Our studies delve into the interaction between receptors and intracellular pathways that regulate metabolic functions. By mapping these pathways, we can identify novel targets for interventions aimed at preventing and treating obesity.

Signaling Molecules

We explore the various signaling molecules that influence metabolic responses and contribute to obesity development. Our research aims to clarify how these molecules can be utilized in designing targeted therapies for obesity-related conditions.

01 02 03 04 05
BLOG

Obesity Blog

Dual-Action Anti-Obesity Strategy: Small-Molecule CNOT6L Inhibitor YL-333P Simultaneously Drives Appetite Suppression and Energy Expenditure

Dual-Action Anti-Obesity Strategy: Small-Molecule CNOT6L Inhibitor YL-333P Simultaneously Drives Appetite Suppression and Energy Expenditure

September 16, 2026
Beyond Body Mass Index: How the OBSCORE Framework Enables Precision Prioritization for Weight Loss Interventions

Beyond Body Mass Index: How the OBSCORE Framework Enables Precision Prioritization for Weight Loss Interventions

September 16, 2026
Engineering Next-Generation Multispecifics: Discovery of AMG 133 as a First-in-Class GIPR Antagonist and GLP-1R Agonist Conjugate for Obesity

Engineering Next-Generation Multispecifics: Discovery of AMG 133 as a First-in-Class GIPR Antagonist and GLP-1R Agonist Conjugate for Obesity

September 16, 2026
Comparative Efficacy of Traditional Chinese Medicine Non-Pharmacological Interventions for Simple Obesity: A Network Meta-Analysis

Comparative Efficacy of Traditional Chinese Medicine Non-Pharmacological Interventions for Simple Obesity: A Network Meta-Analysis

September 16, 2026
Learn More +
CONTACT US

For more information about our services, please feel free to

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

0
Inquiry Basket
Check Out

Recognizing the multifaceted nature of obesity, we leverage our expertise in preclinical research to provide tailored solutions that address the unique challenges faced by our partners in the biotechnology and pharmaceutical industries.

By Molecule Type

By Products

By Services

Contact Us

Copyright © Protheragen. All rights reserved.